BGE-102 (oral NLRP3 inhibitor) is a BioAge Labs, Inc. program in diabetic macular edema. Its next catalyst is a Readout in Q4 2027. Every date links its source.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: diabetic macular edema. Sponsor: BioAge Labs, Inc. (BIOA). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
| Fund | Shares | Value at quarter end | Filing |
|---|---|---|---|
| Cormorant Asset Management | 2,390,605 | $58.6 million | filed August 14, 2026 |
| RA Capital Management | 1,671,648 | $41.0 million | filed August 14, 2026 |
| OrbiMed Advisors | 752,153 | $18.4 million | filed August 14, 2026 |
13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.
The next tracked catalyst for BGE-102 (oral NLRP3 inhibitor) is a Readout in Q4 2027.
No FDA decision for BGE-102 (oral NLRP3 inhibitor) is in our archive yet.
In our records BGE-102 (oral NLRP3 inhibitor) is under review or in development for diabetic macular edema.
BioAge Labs, Inc. (BIOA).
FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.